Skip to content

Spinal anesthesia with 2% lidocaine for cesarean delivery: a randomised double-blind dose-response study

Spinal anesthesia with 2% lidocaine for cesarean delivery: a dose-response study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033421
Enrollment
Unknown
Registered
2020-05-31
Start date
2020-06-16
Completion date
Unknown
Last updated
2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean anesthesia

Interventions

Group L1:2% lidocaine 20 mg+2.0ml CSF
Group L2:2% lidocaine 30 mg+1.5ml CSF
Group L3:2% lidocaine 40 mg+1.0ml CSF
Group L4:2% lidocaine 50 mg+0.5ml CSF

Sponsors

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 36 Years

Inclusion criteria

Inclusion criteria: Including full-term singletons, ASA I-II grade, 18-36 years pregnant women undergoing elective cesarean delivery

Exclusion criteria

Exclusion criteria: 1. Obesity (BMI> 30Kg/m2) 2. Height 175cm 3. Severe cardiovascular and cerebrovascular diseases 4. Combining hypertension and diabetes 5. Combining obstetric-related complications (placenta previa, placental abruption, etc.) 6. Known intrauterine abnormalities 7. Intrauterine growth restriction 8. There are contraindications for epidural puncture and subarachnoid puncture.

Design outcomes

Primary

MeasureTime frame
Success rate of anesthesia;

Secondary

MeasureTime frame
Blood pressure;Sensory block level;Motor block level;Neonatal outcome;Concentration of lidocaine;

Countries

China

Contacts

Public ContactChai Xiaoqing

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

xiaoqingchai@ustc.edu.cn+86 0551-62283912

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026